INTRODUCTION

Vancomycin-resistant Enterococcus (VRE) was first isolated in 1986, and was recently identified as a leading cause of nosocomial infection [1]. VRE colonization before and after solid organ transplantation is associated with an increased risk of VRE infection and has been found to be an independent risk factor for VRE bacteremia in several studies [2,3]. The mortality rate due to VRE bacteremia is reportedly as high as 46% in transplantation patients [4]. However, no previous reports describe a case wherein kidney was transplanted from a donor with VRE colonization. Here, we describe a case of kidney transplantation wherein the organ was taken from a deceased-donor with VRE colonization.

CASE REPORT

A 66-year-old man was admitted to our hospital due to mental deterioration, and intraventricular hemorrhage was detected. Then, the patient underwent urgent placement of an external ventricular drain and started receiving mechanical ventilation therapy. The guardian decided to donate the patient’s organs including kidneys on day 25 of admission. At that time, the blood urea nitrogen and serum creatinine concentrations were 25 mg/dL and 1.0 mg/dL, respectively. The patient had pneumonia, and the serum concentration of C-reactive protein was 38 mg/dL (reference <0.3 mg/dL). His tracheal aspiration showed Acinetobacter baumannii susceptible to ampicillin/sulbactam, piperacillin and imipenem. He had received piperacillin/tazobactam for 14 days. We also detected vancomycin resistant Enterococcus faecium in urine culture and rectal swab (Table 1). However, no organism was detected in blood cultures. After transplantation was decided, we...
administrated linezolid for 2 days before operation. This study was approved by the Institutional Review Board of the Presbyterian Medical Center, Jeonju, Korea (IRB No. E2020-028).

A 52-year-old man received kidney from the deceased donor. He had been on continuous ambulatory peritoneal dialysis for 13 years with original disease of hypertension. After transplantation, his immunosuppressive treatments consisted of induction with basiliximab and a maintenance regimen with tacrolimus, mycophenolate mofetil, and prednisolone. The serum creatinine concentration decreased to 1.4 mg/dL during admission period. The patient discharged on day 20 without any signs of infection. Moreover, VRE was not detected in repeated urine culture and rectal swab during the hospitalization period. At the 3-month follow-up after transplantation, pyuria was not observed in urinary analysis.

**DISCUSSION**

*Enterococci* are one of the most common isolated species causing nosocomial blood stream infections in intensive care unit [1]. Treatment of enterococcal blood stream infections has become more difficult due to the increase of multidrug resistance. VRE prevalence has increased worldwide, so VRE infections are an important cause of hospital-acquired infections globally [5]. The prevalence of VRE colonization in renal transplant recipients was 13.6%, which was as high as those reported for other high-risk groups such as hemodialysis patients [6]. The clinical significance of VRE colonization in hematopoietic stem cell transplantation (HSCT) is controversial. Zirakzadeh et al. [7] reported that pretransplant VRE colonization is associated with an increase in HSCT mortality, whereas VRE colonization on a prior admission was not an independent risk factor for bacteremia in a study reported by Kang et al. [8]. However, very few studies investigated whether donors with VRE colonization are suitable for solid organ transplantation, including kidney transplantation. In our case, VRE was detected in urine culture and rectal swab during hospitalization before organ donation. To our knowledge, this is the first report of using the kidney of a donor with VRE colonization in transplantation.

Recently, there is an increasing number of renal transplantation using deceased donor with infectious risk such as hepatitis C virus and human immunodeficiency virus [9]. However, there is no guideline on whether organs from donors with VRE are acceptable in renal transplantation. The inflammatory markers including C-reactive protein were elevated in this case just before transplantation. Besides pneumonia, the patient might have concomitant urinary tract infection (UTI) due to VRE since the patient had several risk factors of VRE-associated UTI such as sex and indwelling catheter [10]. However, it is not easy for clinicians to differentiate between VRE-associated urinary colonization, asymptomatic bacteriuria, and UTIs [11]. Therefore, we administered linezolid for 2 days after the donation was decided. Considering urgent clinical circumstance of transplantation using deceased donor, transplantation can be performed before the results of donor culture. Therefore, it is essential to check the donor culture results even after transplantation since the transmission of VRE from donor to recipient is possible [12,13]. Because the number of solid organ transplantations using organs from donors with VRE colonization may increase, it is needed to assess this issue and establish guidelines about regarding the use of organs from such donors.

In summary, herein, we report a case wherein a kidney was transplanted from a deceased donor with VRE colonies in urine and rectal swab. After transplantation, VRE

**Table 1. Antimicrobial susceptibility of *Enterococcus faecium* isolated from urine**

| Antibiotics                  | Susceptibility | MIC (µg/mL) |
|------------------------------|----------------|-------------|
| Penicillin                   | R              | ≥64         |
| Ampicillin                   | R              | ≥2          |
| Gentamicin (high-level resistance) | SYN-R      |             |
| Streptomycin (high-level resistance) | SYN-S    |             |
| Ciprofloxacin                | R              | ≥8          |
| Quinupristin/dafopristin     | S              | 0.5         |
| Linezolid                    | S              | 2           |
| Teicoplanin                  | S              | 1           |
| Vancomycin                   | R              | ≥32         |

MIC, minimum inhibitory concentration; R, resistant; S, susceptible; SYN, synergy.
was not detected in recipient's urine and rectal swab.

ACKNOWLEDGMENTS

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Funding/Support
This study was supported by research grant from the Korean Society for Transplantation (2020-02-02002-007).

ORCID
Ji Hye Lim https://orcid.org/0000-0002-3768-2194
Chan Jung Kim https://orcid.org/0000-0003-0726-7800
Ju Hwan Oh https://orcid.org/0000-0002-0914-0179
A Young Cho https://orcid.org/0000-0001-9304-0818
Mi Ok Chang https://orcid.org/0000-0003-1565-9310
Young Suk Kim https://orcid.org/0000-0002-8382-8780
Kwang Young Lee https://orcid.org/0000-0002-5754-1452
In O Sun https://orcid.org/0000-0001-7245-3736

Author Contributions
Conceptualization: JHL, IOS. Data curation: CJK, JHO, JHL. Formal analysis: JHL, AYC, IOS, YSK. Methodology: YSK, MOC, KYL. Writing–original draft, review, & editing: JHL, IOS.

REFERENCES

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.
2. Kim YJ, Kim SI, Choi JY, Yoon SK, You YK, Kim DG. Clinical significance of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci colonization in liver transplant recipients. Korean J Intern Med 2015;30:694-704.
3. Kim YJ, Jun YH, Choi HJ, You YK, Kim DG, Choi JY, et al. Impact of enterococcal bacteremia in liver transplant recipients. Transplant Proc 2019;51:2766–70.
4. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
5. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1:314-25.
6. Freitas MC, Pacheco-Silva A, Barbosa D, Silbert S, Sader H, Sesso R, et al. Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients. BMC Infect Dis 2006;6:133.
7. Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008;41:385-92.
8. Kang Y, Vicente M, Parsad S, Brielmeier B, Pisano J, Landon E, et al. Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients. Transpl Infect Dis 2013;15:466-73.
9. Ruck JM, Segev DL. Expanding deceased donor kidney transplantation: medical risk, infectious risk, hepatitis C virus, and HIV. Curr Opin Nephrol Hypertens 2018;27:445-53.
10. Arias CA, Murray BE. Enterococcus species, Streptococcus gallolyticus group, and Leucomonstoc species. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia, PA: Saunders; 2015. p. 2328-39.
11. Gupta K, Bhadelia N. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am 2014;28:49-59.
12. Bashir A, Attie O, Sullivan M, Sebra R, Singh KV, Altman D, et al. Genomic confirmation of vancomycin-resistant Enterococcus transmission from deceased donor to liver transplant recipient. PLoS One 2017;12:e0170449.
13. Nelloro A, Huprikar S; AST ID Community of Practice. Vancomycin-resistant Enterococcus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13549.